Despite the billions of dollars invested in biomedical R&D, there remains a lack of transparency concerning research findings that do not demonstrate efficacy, never reach completion, or remain behind paywalls. The federal government has issued guidance to make these scientific findings more accessible, but are those efforts paying off; are they having any impact? During the COVID-19 response, we saw an unprecedented level of collaboration among researchers, a rapid sharing of early results and their speedy publication on pre-print servers, online journals, and other platforms. In the aftermath, are those practices continuing, or are we returning to the status quo? Is there a role for patients and nonprofit organizations in contributing data and insisting on open sharing? This panel will discuss persistent challenges to research transparency, the changes needed to transform the current paradigm, and areas where the system is primed to shift towards greater openness and efficiency. 

Moderator

Shamiram Feinglass

Fellow, Aspen Institute

Speakers

Stuart Buck

Executive Director, Good Science Project

Ysabel Duron

Founder and Executive Director, The Latino Cancer Institute

Ekemini Riley

Managing Director, Aligning Science Across Parkinson's (ASAP)

Jeffrey Rothstein

Director and Founder, Robert Packard Center for ALS Research; Founder, Answer ALS Research Program